Start-up
Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: implication for accelerated atherosclerosis in people living with HIV (PLWH) under ART
Learn MoreOngoing
Barriers and Facilitators of the “Sex Now 2022” Venue-Based HIV Self-Testing and Peer-Based Linkage to Care Intervention for Sexual Minority Men, Non-Binary, and Two-Spirit People
Learn MoreResults
Cultural Adaptation of Gay Poz Sex (GPS): A Positive Prevention Program for Gay, HIV-Positive Latino Men in Canada and Colombia
Learn MoreEnrolling
Longitudinal impacts of violence and stigma on HIV care continuum and broader health care access among women living with HIV
Learn MoreEnrolling
The role of female sex hormones and chronic/latent co-infections on cellular aging and comorbidities in women living with HIV
Learn MoreReporting
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Learn MoreEnrolling
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn MoreEnrolling
A randomized trial of doxycycline chemoprophylaxis for the prevention of sexually transmitted infections in gay, bisexual and other men who have sex with men (gbMSM)
Learn MoreEnrolling
Virtual PrEP: Rendering PrEP delivery more efficient using an mHealth intervention and TAF/FTC
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
